Elias served as a Scientist at Tengion, Inc. for six year and has over 20 years of Broad-based background in preclinical (GLP and Non-GLP) experimental studies including the histological and biocompatibility evaluation of human and animal tissues for safety assessment of medical devices, biomaterials and regenerative medicine products; direct experience in design and implementation of preclinical studies from start-up through closeout. Elias earned his Master of Health Science (Medical Laboratory Science) from Quinnipiac University in 1999 and his Bachelor of Science in Microbiology in 1996 from Southern Connecticut State University.
Dr. Basu served as a Director of Process Research and Translation at Tengion, Inc. for six years. Responsibilities included potency assay development and determination of biodistribution and mechanism of action for Tengion’s clinical candidates Neo-Urinary Conduit (NUC) and Neo-Kidney Augment (NKA). Joydeep also led development of Tengion’s Neo-Esophagus and Neo-Intestine preclinical programs. Prior to joining Tengion in 2008, Joydeep spearheaded preclinical translation of Multi-stem and led development of the human artificial chromosome gene therapy platform at Athersys, Inc. Joydeep received his PhD from Cornell University in 1999 and his BA from the University of Cambridge in 1993.
Dr. Lin received his PhD from Wake Forest University in 2008 and his Medical Degree from Dalian Medical University, China in 1999. Current interests are focused on the development of regenerative medicine products using a biomedical approach suitable to clinical therapies to gain a deeper understanding of the cellular and biological processes at a molecular level.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.